Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
Advertisement

Related Content

Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
Hospira's Precedex Phase IV Trial Postponed To 2005
Hospira's Precedex Phase IV Trial Postponed To 2005
Hospira Spin-Off From Abbott "Progressing Smoothly," CEO Says
Hospira Spin-Off From Abbott "Progressing Smoothly," CEO Says
Hospira Becomes GPhA Member
Prevacid Decline Is Weak Spot In Otherwise Strong Quarter For Abbott
Abbott Sets Hospira Spin-Off For May 3; Market Cap Estimated At $5 Bil.
Abbott Sets Hospira Spin-Off For May 3; Market Cap Estimated At $5 Bil.

Topics

Advertisement
UsernamePublicRestriction

Register

PS059572

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel